Ruth Duncan http://www.ruthduncan.co.uk

Updated August 2017

Recent Reviews Polymer Therapeutics

2017 - Duncan R (2017) Polymer Therapeutics at a Crossroads? Finding the path for improved translation in the 21st Century. J. Drug Targeting in press.

2014 - Duncan R (2014) Polymer Therapeutics Top 10 Selling Pharmaceuticals- what next ? J. Controlled Rel. 190, 371-380.

2013 - Duncan R and Vicent MJ (2013) Polymer therapeutics prospects for the 21st century: The end of the beginning. Adv. Drug Delive. Rev. 65, 60-70.

2011 - Duncan R (2011) Polymer Therapeutics as Nanomedicines: New Perspectives. Curr. Opin. Biotechnol. 22, 1-10.

2009 - POLYMER THERAPEUTICS PRECLINICAL SAFETY AND REGULATORY CONSIDERATIONS

Gaspar, R. and Duncan, R. (2009) Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. In: Vicent, M. J. and Duncan, R. (Eds. Theme Issue: Polymer Therapeutics: Clinical Applications and Challenges for Development. Adv. Drug Del. Rev. 61, 1220-1231. 

SOME KEY REFERENCES

Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nature Reviews Cancer 6 688-701
-----------------------------
Duncan R (2003) The dawning era of polymer therapeutics. Nature Reviews Drug Discovery 2 (5) 347-360.
-----------------------------
Duncan R and Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv. Drug Del. Rev. 57,2215-2237.
------------------------------
Duncan R (1992) Drug-Polymer Conjugates: potential for improved chemotherapy.Anti-Cancer Drugs 3, 175-210
------------------------------
Duncan R, Dimitrijevic S and Evagorou E. (1996) The role of polymer conjugates in te diagnosis and treatment of cancer. S.T.P. Pharma 6,237-263.

You are viewing the text version of this site.

To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.

Need help? check the requirements page.


Get Flash Player